![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD163 |
Gene summary for CD163 |
![]() |
Gene information | Species | Human | Gene symbol | CD163 | Gene ID | 9332 |
Gene name | CD163 molecule | |
Gene Alias | M130 | |
Cytomap | 12p13.31 | |
Gene Type | protein-coding | GO ID | GO:0002526 | UniProtAcc | Q86VB7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9332 | CD163 | HCC1_Meng | Human | Liver | HCC | 8.69e-25 | 7.25e-02 | 0.0246 |
9332 | CD163 | HCC1 | Human | Liver | HCC | 3.33e-04 | 5.06e-01 | 0.5336 |
9332 | CD163 | Pt13.a | Human | Liver | HCC | 3.13e-05 | 2.34e-01 | 0.021 |
9332 | CD163 | Pt13.c | Human | Liver | HCC | 6.33e-12 | 6.58e-01 | 0.0076 |
9332 | CD163 | Pt14.d | Human | Liver | HCC | 3.53e-21 | 5.72e-01 | 0.0143 |
9332 | CD163 | S028 | Human | Liver | HCC | 8.28e-07 | 2.13e-01 | 0.2503 |
9332 | CD163 | S029 | Human | Liver | HCC | 4.49e-03 | 3.13e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
GO:00069532 | Liver | HCC | acute-phase response | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD163 | SNV | Missense_Mutation | c.1387N>A | p.Asp463Asn | p.D463N | Q86VB7 | protein_coding | tolerated(0.44) | benign(0.14) | TCGA-46-3767-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CD163 | SNV | Missense_Mutation | novel | c.2482N>T | p.Ser828Cys | p.S828C | Q86VB7 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-56-7730-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
CD163 | SNV | Missense_Mutation | novel | c.1163N>C | p.Val388Ala | p.V388A | Q86VB7 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-56-7731-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD163 | SNV | Missense_Mutation | novel | c.757G>A | p.Asp253Asn | p.D253N | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-56-8504-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CD163 | SNV | Missense_Mutation | novel | c.1967N>T | p.Glu656Val | p.E656V | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-60-2703-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CD163 | SNV | Missense_Mutation | c.895G>C | p.Asp299His | p.D299H | Q86VB7 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-66-2770-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CD163 | SNV | Missense_Mutation | novel | c.400N>C | p.Gly134Arg | p.G134R | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-68-7757-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CD163 | SNV | Missense_Mutation | novel | c.3259G>A | p.Gly1087Arg | p.G1087R | Q86VB7 | protein_coding | tolerated(0.36) | benign(0.089) | TCGA-77-7338-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD163 | SNV | Missense_Mutation | novel | c.1087G>T | p.Val363Leu | p.V363L | Q86VB7 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-85-7950-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD163 | SNV | Missense_Mutation | novel | c.353N>C | p.Val118Ala | p.V118A | Q86VB7 | protein_coding | deleterious(0.01) | benign(0.328) | TCGA-85-A511-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9332 | CD163 | DRUGGABLE GENOME, KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | GLUCOCORTICOID | 9712057 | ||
9332 | CD163 | DRUGGABLE GENOME, KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | FLUTICASONE PROPIONATE | 9712057 |
Page: 1 |